The Promise of Neuroprotective Agents in Parkinson’s Disease

Parkinson’s disease (PD) is characterized by loss of dopamine neurons in the substantia nigra of the brain. Since there are limited treatment options for PD, neuroprotective agents are currently being tested as a means to slow disease progression. Agents targeting oxidative stress, mitochondrial dys...

Descripción completa

Detalles Bibliográficos
Autores principales: Seidl, Stacey E., Potashkin, Judith A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2011
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221408/
https://www.ncbi.nlm.nih.gov/pubmed/22125548
http://dx.doi.org/10.3389/fneur.2011.00068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221408/
https://www.ncbi.nlm.nih.gov/pubmed/22125548
http://dx.doi.org/10.3389/fneur.2011.00068

Ejemplares similares